Jefferies upgraded Assembly Biosciences to Buy from Hold with a price target of $35, up from $2. The upcoming Phase IA data for the company’s long acting oral for recurrent genital herpes should support once weekly dosing with good safety, the analyst tells investors in a research note. The firm says the mechanism is already “derisked” by pritelivir, which showed positive data versus standard of care for genital herpes but was discontinued due to toxicity. Assembly is more potent and safety is unlikely to be an issue, contends Jefferies.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue